Health
Omicron-specific booster: Moderna kicks off clinical trials
Third shot of Moderna original coronavirus vaccine increase neutralizing antibodies, claims the company.
![Omicron-specific booster: Moderna kicks off clinical trials](/media/14502/conversions/Moderna-vaccine-1280x720.webp)
Massachusetts: Moderna Inc said on Wednesday it had started a mid-stage study, testing a booster dose of its COVID-19 vaccine specifically designed to target the Omicron coronavirus variant, a day after rival Pfizer Inc launched a similar trial.
The company said while a third shot of its original coronavirus vaccine increased neutralizing antibodies against the variant at the lower dose, their levels declined six months after the booster dose was administered.
However, neutralizing antibodies remained detectable in all participants, Moderna said.
While studies have indicated that Omicron results in a less severe COVID-19 than seen during previous waves, the variant has quickly become dominant in many parts of the world, driving up infections and straining healthcare systems.
The variant currently accounts for 99.9% of the COVID-19 cases in the Unites States.
Pfizer and its partner BioNTech started a clinical trial on Tuesday to test a new version of their vaccine specifically tailored to the Omicron variant.
Moderna said it would study its Omicron-specific booster in adults aged 18 years and older.
It would test the booster in individuals who received only the two-dose primary series of Moderna's original vaccine, mRNA-1273, and also in those who received the primary series and a booster dose of the same vaccine, the company said.
Moderna plans to enroll about 300 participants in each of the two groups in the study.
Three studies, led by the U.S. Centers for Disease Control and Prevention have shown that a third dose of an mRNA vaccine, such as those from Pfizer and Moderna, is key to fighting the Omicron variant.
Some countries have already started offering additional booster doses, but a recent study from Israel showed that while a fourth dose of an mRNA vaccine boosted antibodies, the level was not high enough to prevent an Omicron infection.
SOURCE: Reuters
-
Pakistan 1 day ago
JI Emir demands forensic audit of IPPs, public disclosure of agreements
-
World 2 days ago
Magnitude 7.3 earthquake in Chile
-
Pakistan 1 day ago
Justice given to a man who didn't even seek it, says Nawaz
-
Regional 2 days ago
KP to increase salaries
-
Regional 1 day ago
Supporters of May 9 rioters to be considered facilitators: Bokhari
-
Weather 1 day ago
Parts of Karachi witness moderate rain
-
Technology 1 day ago
PM orders early completion of Islamabad Tech Park
-
Business 2 days ago
Gold price plummets by Rs3,000 per tola in Pakistan